CIPROFLOXACIN tablet

Land: Verenigde Staten

Taal: Engels

Bron: NLM (National Library of Medicine)

Werkstoffen:

CIPROFLOXACIN HYDROCHLORIDE (UNII: 4BA73M5E37) (CIPROFLOXACIN - UNII:5E8K9I0O4U)

Beschikbaar vanaf:

Unit Dose Services

INN (Algemene Internationale Benaming):

CIPROFLOXACIN HYDROCHLORIDE

Samenstelling:

CIPROFLOXACIN 250 mg

Prescription-type:

PRESCRIPTION DRUG

Autorisatie-status:

Abbreviated New Drug Application

Productkenmerken

CIPROFLOXACIN - CIPROFLOXACIN TABLET
UNIT DOSE SERVICES
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
CIPROFLOXACIN SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION FOR CIPROFLOXACIN.
CIPROFLOXACIN (HYDROCHLORIDE) TABLETS FOR ORAL USE
INITIAL U.S. APPROVAL: 1987
WARNING: TENDON EFFECTS AND MYASTHENIA GRAVIS
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
FLUOROQUINOLONES, INCLUDING CIPROFLOXACIN, ARE ASSOCIATED WITH AN
INCREASED RISK OF TENDINITIS AND
TENDON RUPTURE IN ALL AGES. THIS RISK IS FURTHER INCREASED IN OLDER
PATIENTS USUALLY OVER 60 YEARS OF AGE,
IN PATIENTS TAKING CORTICOSTEROID DRUGS, AND IN PATIENTS WITH KIDNEY,
HEART OR LUNG TRANSPLANTS _[SEE_
_WARNINGS AND PRECAUTIONS (5.1)]._
FLUOROQUINOLONES, INCLUDING CIPROFLOXACIN, MAY EXACERBATE MUSCLE
WEAKNESS IN PERSONS WITH
MYASTHENIA GRAVIS. AVOID CIPROFLOXACIN IN PATIENTS WITH KNOWN HISTORY
OF MYASTHENIA GRAVIS _[SEE_
_WARNINGS AND PRECAUTIONS (5.2)]._
RECENT MAJOR CHANGES
Indications and Usage, Plague (1.14) 03/2015
Dosage and Administration, Adults (2.1), Pediatrics (2.2) 03/2015
INDICATIONS AND USAGE
Ciprofloxacin is a fluoroquinolone antibacterial indicated in adults
(≥18 years of age) with infections caused by designated,
susceptible bacteria and in pediatric patients where indicated.
Urinary tract infections (1.1) and Acute uncomplicated cystitis (1.2)
Chronic bacterial prostatitis (1.3)
Lower respiratory tract infections (1.4)
Acute sinusitis (1.5)
Skin and skin structure infections (1.6)
Bone and joint infections (1.7)
Complicated intra-abdominal infections (1.8)
Infectious diarrhea (1.9)
Typhoid fever (enteric fever) (1.10)
Uncomplicated cervical and urethral gonorrhea (1.11)
Complicated urinary tract infections and pyelonephritis in pediatric
patients (1.12)
Inhalational anthrax post-exposure in adult and pediatric patients
(1.13)
Plague in adult and pediatric patients (1.14)
To reduce the development of drug-resistant bacteria and maintain the
effectiv